Stock GOSS GOSSAMER BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Gossamer Bio, Inc.

Equities

GOSS

US38341P1021

Market Closed - Nasdaq
Other stock markets
 21:00:00 14/05/2024 BST 		5-day change 1st Jan Change
0.7328 USD +1.78% Intraday chart for Gossamer Bio, Inc. +0.18% -19.69%
05-07 Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-06 Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
BU
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
Gossamer Bio: Q1 Earnings Snapshot
AQ
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
BU
Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Gossamer bio announces publication of torrey phase 2 results in the lancet respiratory medicine
AQ
Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications
CI
Transcript : Chiesi Farmaceutici S.p.A., Gossamer Bio, Inc. - M&A Call
Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment
RE
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
BU
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
BU
Gossamer Bio Announces Publication of Torrey Phase 2 Results in the Lancet Respiratory Medicine
CI
Transcript : Gossamer Bio, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 07:30 AM
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
BU
Gossamer Bio Announces Board of Directors Appointments
CI
Goldman Sachs Adjusts Price Target on Gossamer Bio to $8 From $9, Maintains Buy Rating
MT
Gossamer Bio: Q4 Earnings Snapshot
AQ
Gossamer Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
BU
Gossamer Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GOSS Stock
  4. News Gossamer Bio, Inc.